On August 5, 2026, the FDA approved Moderna's mFLUSIVA — the first flu vaccine built on mRNA technology — for adults 50 and older. Vinay Prasad, FDA's director of biologics (CBER), issued a refusal-to-file letter in February, declining to even review the application. Two weeks later, after Moderna pushed back publicly, the agency reversed course. The FDA's advisory committee voted 9-0 in favor in June. Adults 50-64 got standard approval; adults 65 and older got accelerated approval pending additional trials. On August 19, a team of three doctors sent a 34-page data reanalysis to HHS Secretary Robert F. Kennedy Jr., FDA, CDC, and NIH, formally requesting withdrawal before flu season begins.

1. The Science Backs This Vaccine (VRBPAC, Moderna, Dr. Céline Gounder)

The trial data is clear: mFLUSIVA outperforms the standard flu shot, and the advisory committee said so unanimously.

It's 27% more effective than standard flu shots. In the FLUENT trial of roughly 40,000 people, adults 50-64 who received mFLUSIVA were 27% less likely to contract test-confirmed flu compared to a standard-dose shot. That's a meaningful gap for a disease that hospitalizes hundreds of thousands of Americans every winter.

The advisory committee wasn't close. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that mFLUSIVA's benefits outweigh its risks for adults 50 and older. Independent experts with no stake in the outcome found the evidence sufficient.

mRNA vaccines can adapt faster than any alternative. Dr. Céline Gounder, a CBS News medical analyst, noted that egg-based flu vaccine manufacturing takes 18 months to scale to pandemic-level quantities, while mRNA production can move "much more quickly." If next year's circulating strain diverges from predictions — which happens regularly — that speed is the difference between a useful shot and a missed season.

2. The Data Reanalysis Says Pull It (Peter McCullough, Nicolas Hulscher, John Catanzaro)

The formal withdrawal request argues the risk-benefit math is worse than any vaccine in recent memory.

You'd vaccinate over 5,000 people to prevent one hospitalization. The August 19 analysis calculated that to prevent a single influenza hospitalization, approximately 5,017 adults would need to receive mFLUSIVA instead of a standard flu shot — at the cost of roughly 2 excess unexplained deaths, 278 disabling Grade 3 reactions, and 3,798 total adverse events.

The death and disability signals aren't statistical noise. Unexplained deaths were 2.55 times more frequent in the mFLUSIVA group, and Grade 3 systemic reactions — severe enough to be temporarily disabling — were more than six times as common as with the standard flu shot. Peter McCullough, MD, MPH, a cardiologist who has testified before the U.S. Senate on vaccine risks, led the reanalysis team along with Nicolas Hulscher, MPH, and John Catanzaro, NMD, PhD.

The 65+ approval reveals the deepest problem. The FDA gave the highest-risk age group — people most likely to die from flu — only accelerated approval, meaning it cleared mFLUSIVA before Moderna had comparative trial data against the high-dose and adjuvanted vaccines the FDA already recommends for that age group. The evidentiary gap is largest where it matters most.

3. But Even If It's Safe, Trust Is the Real Crisis (KFF, CIDRAP editorial)

The chaotic approval process handed critics ammunition — and the eligible population was already skeptical of mRNA.

Most people who could take this vaccine don't trust the technology. KFF polling from April 2025 — released two weeks ago when mFLUSIVA was approved — found that a majority of adults 50 and older are uncertain whether mRNA vaccines are safe. Even among Democrats — the group most favorable to mRNA — roughly half remain unsure. Democrats were about three times as likely as Republicans to call mRNA safe.

That reversal looks like corporate pressure, not science. Prasad refused to review the application in February, then reversed two weeks later with no public explanation — after Moderna disclosed the FDA's decision and expressed its displeasure. A vaccine expert quoted by CBS News said: "We don't have any idea why they reversed course. That's part of the problem." A CIDRAP op-ed titled "The FDA refused to review a flu vaccine, contrary to evidence. Now the agency reversed itself" made the same case in detail.

The anti-mRNA administration just approved an mRNA vaccine. Kennedy has slashed $500 million in mRNA contracts and halted 22 vaccine development projects using the technology. His FDA just approved the first mRNA flu vaccine in U.S. history. Right now, that contradiction makes it harder to tell any skeptic this approval went through neutral science.

Where This Lands

The 9-0 advisory vote gave the FDA legitimate scientific cover to approve mFLUSIVA, and the trial data shows it outperforms the current standard. The McCullough reanalysis is a formal submission to Kennedy — not a social media post — so HHS and FDA will have to respond publicly on the risk-benefit numbers. The real test isn't whether regulators approved it. It's whether the eligible population shows up for a vaccine most of them are already uncertain about, when the FDA ran one of the messiest approval processes in recent memory.

Sources